SCHEMBL20119862

SCHEMBL20119862

CC(C)(CCC(C)(C)c1nccs1)c1ccco1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.35
ALDH1A1 P00352 3/20 0.33
LMNA P02545 2/20 0.33
ADORA2A P29274 2/20 0.32
ADORA1 P30542 2/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
MEN1 O00255 3/20 0.32
KMT2A Q03164 3/20 0.32
HIF1A Q16665 1/20 0.32
PPARG P37231 1/20 0.31
NCOR2 Q9Y618 1/20 0.31
PKM P14618 1/20 0.31
ADRB2 P07550 1/20 0.31
ALOX5 P09917 1/20 0.31
NPC1 O15118 1/20 0.30
POLB P06746 1/20 0.30
AGTR1 P30556 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8612890 0.79 MAPT (0.40) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL27097384 0.77
SCHEMBL667810 0.73 MAPT (0.36) MAPTALDH1A1LMNAMEN1KMT2A
SCHEMBL21236276 0.72 ALOX5 (0.36) ALDH1A1MEN1KMT2AHIF1APKM
SCHEMBL21720154 0.69 L3MBTL1 (0.36) ALDH1A1ADORA2ACYP2C9ALOX5SMN1; SMN2
SCHEMBL24897434 0.69
SCHEMBL12243140 0.68 FBP1 (0.38) ALDH1A1MEN1KMT2AHIF1APKM
SCHEMBL21191566 0.67 CNR2 (0.36) ALOX5L3MBTL1
SCHEMBL25854596 0.67 CNR2 (0.36) ALOX5L3MBTL1
SCHEMBL21482041 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 MAPT 2133/4885ALDH1A1 2393/4885LMNA 639/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 MAPT 2133/4885ALDH1A1 2393/4885LMNA 639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.